What is Stifel Canada’s Forecast for TSE:HLS Q1 Earnings?

HLS Therapeutics Inc. (TSE:HLS) – Equities researchers at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for shares of HLS Therapeutics in a report released on Tuesday, March 25th. Stifel Canada analyst J. Keywood anticipates that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.

Separately, Stifel Nicolaus boosted their price target on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the company a “hold” rating in a research report on Wednesday.

HLS Therapeutics Price Performance

TSE HLS opened at C$4.66 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The company has a market cap of C$103.67 million, a PE ratio of -4.67 and a beta of 1.07. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The firm’s 50-day simple moving average is C$4.19 and its two-hundred day simple moving average is C$3.81.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.